Proceedings from the Canadian Society of Respiratory Therapists Annual Education Conference: May 26–28, 2016 • Ottawa, Ontario

We are pleased to present a select number of abstracts from the proceedings of the CSRT Annual Education Conference. Held in Ottawa, Ontario, May 26 to 28, 2016, this conference included topics delivered by international, national and regional individuals with expertise in various areas of respiratory therapy practice, including quality assurance, patient safety, evidence-based practice, patient and family centred care, research and innovation. As evidenced by the following abstracts, the work of our colleagues in 2016 highlighted current research and practice innovations led by RTs. We have made every effort to include all abstracts accepted by the Program Committee before the publication deadline; however, please note that this collection does not represent the entire program (available at www.csrt.com). The editorial board looks forward to receiving manuscripts from this conference for consideration for publication in the Canadian Journal of Respiratory Therapy in order to continue building the body of knowledge specific to our profession. Please note these abstracts have not been peer reviewed. Keynote sPeaKers 01 oPioid-induced resPiratory dePression f marquis md ma frcP(c) ciusss de l'est-de-l'Île-de-montréal, université de montréal, Qc [email protected] Opioid-induced respiratory depression, commonly defined as a respiratory rate of less than 8 breaths per minute with a lowered blood oxygen saturation in the context of opioid administration, has been feared since the first days of opioid use in clinics. Mediated by the same μ-receptors responsible for opioid analgesia, this relatively low (0.5%) but highly preventable source of morbidity and mortality is always a risk. While the administration route of the opioid is not related to the incidence of respiratory depression, very potent, long-acting preparations and infusions put the patient at risk, as does the co-administration of certain drugs—especially sedatives or drugs having a significant impact on opioids metabolism through CYP450 or change in renal function. Relatively healthy patients are rarely victims of opioid respiratory depression. However, the " very " patients (very young, very old, very obese and very sick) and patients with sleep apnea, are more susceptible. They should be closely evaluated / monitored to ensure adequate pain control without respiratory depression. In the setting of opioid-induced respiratory depression, one could try non-pharmacological approaches, such as non-opioid pain control (pharmacological or other) and verbal/physical stimuli, while carefully monitoring the patient. Should opioid reversal be needed, naloxone should be given by any trained health professional, in small boluses of 40-100 mcg every 2 minutes, titrated to respiratory drive, …